文献速递银屑病与炎症性皮肤病

卡泊三醇/二丙酸倍他米松泡沫剂在银屑病中快速起效,包括较严重患者

Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-03-27

本汇总分析纳入三项II/III期试验,比较卡泊三醇50 μg/g联合二丙酸倍他米松0.5 mg/g泡沫剂(Cal/BD泡沫)与泡沫载体在轻至重度银屑病早期时间点的疗效。结果显示Cal/BD泡沫在第1周即显著优于载体,第4周达到mPASI和DLQI目标的比例更高,在较严重患者中也一致。

要点

  • Cal/BD泡沫第1周即显现优于载体的mPASI改善。
  • 第4周Cal/BD泡沫组达到mPASI 0、≤1、≤3、≤5的比例均显著更高。
  • 基线mPASI>10或DLQI>10的患者中Cal/BD泡沫同样更有效。

核心结论

  • Cal/BD泡沫起效快且疗效优于泡沫载体,即使在较严重银屑病患者中也是如此。

研究设计与样本

  • 三项II/III期试验的汇总分析,评估Cal/BD泡沫与泡沫载体在轻至重度银屑病早期时间点的疗效。

主要发现

  • 第4周Cal/BD泡沫组 vs 载体组达到mPASI 0为15.1% vs 1.0%,≤1为41.4% vs 5.2%,≤3为78.5% vs 29.2%,≤5为90.2% vs 62.5%(所有目标P<0.001)。
  • 第1周Cal/BD泡沫组 vs 载体组达到mPASI≤1为6.8% vs 1.5%(P<0.01),≤3为40.4% vs 22.8%(P<0.001),≤5为69.7% vs 50.8%(P<0.001)。
  • 基线mPASI>10患者中,第4周Cal/BD泡沫组 vs 载体组达到mPASI≤1为20.2% vs 5.9%(P<0.05),≤3为49.2% vs 8.8%(P<0.001),≤5为63.7% vs 26.5%(P<0.001)。
  • 基线DLQI>10患者中,第4周Cal/BD泡沫组 vs 载体组达到DLQI≤1为25.0% vs 4%(P=0.001),DLQI 0为17.4% vs 2.0%(P=0.006)。

临床怎么用

  • Cal/BD泡沫可用于期望快速起效的轻至重度银屑病患者,包括局部治疗可管理的较严重患者。
  • 快速起效可能有助于管理患者预期并提高依从性,从而提升局部治疗整体效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effectiveness of topical therapies in psoriasis is dependent on, amongst other factors, patient adherence. Together with treatment effectiveness and reduction of symptoms, speed of onset and health-related quality of life (HRQoL) are important influencers of adherence. METHODS: This pooled analysis of three Phase II/III trials evaluated the efficacy of topical fixed-dose combination calcipotriol 50 μg/g plus betamethasone dipropionate 0.5 mg/g cutaneous foam (Cal/BD foam) vs. foam vehicle at early timepoints in mild-to-severe psoriasis using clinically meaningful modified Psoriasis Area and Severity Index (mPASI) and Dermatology Life Quality Index (DLQI) targets. RESULTS: A greater proportion of Cal/BD-foam- vs. foam-vehicle-treated patients achieved absolute mPASI targets 0 (15.1% vs. 1.0%), ≤1 (41.4% vs. 5.2%), ≤3 (78.5% vs. 29.2%) and ≤5 (90.2% vs. 62.5%) at week 4 (P < 0.001; all targets). Significant differences between Cal/BD-foam- vs. foam-vehicle-treated patients were observed as early as week 1 in those achieving mPASI ≤1 (6.8% vs. 1.5%; P < 0.01), ≤3 (40.4% vs. 22.8%; P < 0.001) and ≤5 (69.7% vs. 50.8%; P < 0.001). In patients with more severe psoriasis (baseline mPASI >10), a greater proportion of Cal/BD-foam- vs. foam-vehicle-treated patients achieved mPASI ≤1 (20.2% vs. 5.9%; P < 0.05), ≤3 (49.2% vs. 8.8%; P < 0.001) and ≤5 (63.7% vs. 26.5%; P < 0.001) at week 4. In patients with severely impaired HRQoL (baseline DLQI >10), a greater proportion of Cal/BD-foam- vs. foam-vehicle-treated patients achieved target DLQI ≤1 or 0 (week 4: DLQI ≤1, 25.0% vs. 4%; P = 0.001; DLQI 0, 17.4% vs. 2.0%; P = 0.006). CONCLUSION: We report rapid onset of action and greater efficacy with Cal/BD foam vs. foam vehicle, even in patients with more severe psoriasis, manageable with topical treatments. This may support physician management of patient expectations and improve patient adherence, translating into overall topical treatment effectiveness.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Pink AE, Jalili A, Berg P, et al. Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease. J Eur Acad Dermatol Venereol. 2019. PMID: 30916417. doi:10.1111/jdv.15398

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。